Activities of (Poly)phenolic Antioxidants and Other Natural Autophagy Modulators in the Treatment of Sanfilippo Disease: Remarkable Efficacy of Resveratrol in Cellular and Animal Models
-
Published:2022-11-07
Issue:1
Volume:20
Page:254-271
-
ISSN:1933-7213
-
Container-title:Neurotherapeutics
-
language:en
-
Short-container-title:Neurotherapeutics
Author:
Rintz Estera, Podlacha Magdalena, Cyske Zuzanna, Pierzynowska Karolina, Węgrzyn Grzegorz, Gaffke LidiaORCID
Abstract
AbstractSanfilippo disease, caused by mutations in the genes encoding heparan sulfate (HS) (a glycosaminoglycan; GAG) degradation enzymes, is a mucopolysaccharidosis (MPS), which is also known as MPS type III, and is characterized by subtypes A, B, C, and D, depending on identity of the dysfunctional enzyme. The lack of activity or low residual activity of an HS-degrading enzyme leads to excess HS in the cells, impairing the functions of different types of cells, including neurons. The disease usually leads to serious psychomotor dysfunction and death before adulthood. In this work, we show that the use of molecules known as dietary (poly)phenolic antioxidants and other natural compounds known as autophagy activators (genistein, capsaicin, curcumin, resveratrol, trehalose, and calcitriol) leads to accelerated degradation of accumulated HS in the fibroblasts of all subtypes of MPS III. Both the cytotoxicity tests we performed and the available literature data indicated that the use of selected autophagy inducers was safe. Since it showed the highest effectivity in cellular models, resveratrol efficacy was tested in experiments with a mouse model of MPS IIIB. Urinary GAG levels were normalized in MPS IIIB mice treated with 50 mg/kg/day resveratrol for 12 weeks or longer. Behavioral tests indicated complete correction of hyperactivity and anxiety in these animals. Biochemical analyses indicated that administration of resveratrol caused autophagy stimulation through an mTOR-independent pathway in the brains and livers of the MPS IIIB mice. These results indicate the potential use of resveratrol (and possibly other autophagy stimulators) in the treatment of Sanfilippo disease.
Funder
Narodowe Centrum Nauki Fundacja Sanfilippo Poland
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Neurology (clinical),Pharmacology
Reference79 articles.
1. Węgrzyn G, Pierzynowska K, Jakobkiewicz-Banecka J, et al. Mucopolysaccharidosis type III: clinical features, biochemistry, diagnosis, genetics, and treatment. In: Mucopolysaccharidoses Update; Tomatsu S, Lavery C, Giugliani R, Hermatz P, Scarpa M, Węgrzyn G, Orii T, Eds. Nova Publishers: Hauppauge, NY, USA, 2018; Volume 1, pp. 211–233. 2. Pierzynowska K, Rintz E, Gaffke L, et al. Mucopolysaccharidosis type III (Sanfilippo disease) subtypes A, B, C, D: molecular mechanism and therapeutic effect. In: Tomatsu S, Lavery C, Giugliani R, Hermatz P, Scarpa M, Węgrzyn G, Orii T, editors., et al., Mucopolysaccharidoses Update. Hauppauge, NY, USA: Nova Publishers; 2018. p. 51–101. 3. Heon-Roberts R, Nguyen ALA, Pshezhetsky AV. Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease. J Clin Med. 2020;9:344. https://doi.org/10.3390/jcm9020344. 4. Benetó N, Vilageliu L, Grinberg D, Canals I. Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches. Int J Mol Sci. 2020;21:7819. https://doi.org/10.3390/ijms21217819. 5. Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013;102:462–70.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|